Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

CUDC-101

Generic Name: CUDC-101

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₄O_₄

CAS Number: 1012054-59-9

Unique Ingredient Identifier: 1A7Y9MP123

Overview

CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.

Background

CUDC-101 has been used in trials studying the treatment of Cancer, Tumors, Liver Cancer, Breast Cancer, and Gastric Cancer, among others.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients

Phase 1

Terminated

Posted: 2012/10/08

Sponsor:Curis, Inc.

ID:NCT01702285

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Phase 1

Completed

Posted: 2011/06/29

Sponsor:Curis, Inc.

ID:NCT01384799

A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors

Phase 1

Completed

Posted: 2010/07/29

Sponsor:Curis, Inc.

ID:NCT01171924

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of CUDC-101 in Patients With Advanced Solid Tumors

Phase 1

Completed

Posted: 2008/08/06

Sponsor:Curis, Inc.

ID:NCT00728793

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

No news found

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy